Feb 9, 2023 | 2023, Press Releases, Scientific
We are delighted to share the exciting journey of one of our talented PhD students Sara Puglioli, which has recently been covered in a CHEM article (Cell Press). Over the last years, Philochem AG has established industrial Ph.D. programs in collaboration with several...Feb 2, 2023 | 2023, Press Releases, Scientific
Philogen announces the publication of a study in the peer-reviewed journal “Pharmaceutics” describing the development and the in vitro/vivo characterization of a novel interferon-gamma (IFNg) based antibody fusion protein. The paper can be accessed from the...Dec 1, 2022 | 2022, Press Releases, Scientific
The management team to hold a Webinar on Dec 1, 2022, at 10:00 ET / 15:00 GMT / 16:00 CET (Please find the link for the webinar here). Corporate_Update_Dec 1Nov 18, 2022 | 2022, Press Releases, Scientific
The study describes the development of a novel anti-PD-1 antibody that shows potent blockade of PD-1 with a different recognition mechanism compared to anti-PD-1 antibodies that have recently reached the market. For more detailsNov 11, 2022 | 2022, Press Releases, Scientific
The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More detailsNov 7, 2022 | 2022, Press Releases, Scientific
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors. The...
Recent Comments